Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS news (Ticker: ARTV), a resource for investors and traders seeking the latest updates and insights on ARTIVA BIOTHERAPEUTICS stock.
Artiva Biotherapeutics develops cell therapies for autoimmune diseases and cancers, led by AlloNK® (AB-101), an allogeneic, off-the-shelf, non-genetically modified and cryopreserved NK cell therapy candidate. Company updates center on AlloNK clinical data in B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, and on its use with anti-CD20 monoclonal antibodies such as rituximab or obinutuzumab to drive B-cell depletion.
Recurring developments also cover quarterly and annual financial results, balance sheet disclosures, biotechnology conference participation, board and executive appointments, and equity award activity tied to Artiva’s public-company governance.
Artiva Biotherapeutics (Nasdaq: ARTV) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 1:10 p.m. EST in Boston.
Artiva management will meet registered investors and the audio webcast plus archived recording will be available on the company investor website for 90 days.
Artiva (Nasdaq: ARTV) appointed Thad Huston as Chief Financial Officer and approved a 220,000 restricted stock unit inducement grant. Mr. Huston brings over 30 years of finance, commercial and operations leadership, including roles at Galapagos and Kite Pharma.
The RSUs vest over four years, contingent on filing a Form S-8, and Artiva says the hire supports progress toward FDA feedback and rheumatoid arthritis clinical data in H1 2026.
Artiva Biotherapeutics (Nasdaq: ARTV) appointed Elaine Sorg to its board on Feb 19, 2026. Ms. Sorg brings 35+ years of commercial biopharma experience, including leading U.S. commercialization for major immunology therapies.
The company said her expertise will support upcoming clinical activity readouts for AlloNK in rheumatoid arthritis and engagement with the FDA on a registrational trial.
Artiva Biotherapeutics (Nasdaq: ARTV) will present at the 2026 Transplantation & Cellular Therapy Tandem Meetings in Salt Lake City, Feb 4–7, 2026. Artiva will feature poster presentations on Feb 5, 2026 at 6:30 pm MST covering: the cost-effectiveness of AB-101/AlloNK administered in an outpatient community rheumatology practice versus CAR-T treatments, and continued durability data for AlloNK in relapsed/refractory Non-Hodgkin Lymphoma from a multi-center Phase 1/2 trial. Poster IDs are 440 (health services/cost-effectiveness) and 511 (lymphoma clinical durability); authors listed include Nicholas Veomett, Ph.D. and Umer Farooq, M.D. For full abstracts, consult the 2026 Tandem Meetings program.
NanoSyrinx (ARTV) appointed Thomas J. Farrell as Chief Executive Officer and Director effective Jan 8, 2026, succeeding founder Joe Healey, who will remain involved to ensure continuity.
Farrell brings 25+ years in biotherapeutics, served as founding CEO of two NASDAQ-listed companies, raised over $500 million in financing, and has led programs from discovery through clinical trials. NanoSyrinx is transitioning from platform development to building a clinical pipeline for its Nanosyringe intracellular delivery technology, which enables direct cytosolic delivery of protein therapeutics. Farrell will be in San Francisco during the J.P. Morgan Healthcare Conference (Jan 12–15, 2026) and is available for investor and partner discussions.
Artiva Biotherapeutics (Nasdaq: ARTV) reported positive initial safety and translational data for AlloNK + anti-CD20 mAb in autoimmune disease as of Oct 1, 2025. Across 32 patients treated (outpatient/community settings), AlloNK was generally well tolerated with no CRS, ICANS, graft-versus-host disease, or AlloNK-related Grade 3+ TEAEs reported.
Translational readouts showed non-quantifiable peripheral CD19+ B cells by Day 13 in all 23 patients with samples analyzed, including confirmation by a high-sensitivity assay. Artiva plans to share initial clinical responses and pursue FDA interactions on a pivotal refractory RA trial in 1H 2026.
Artiva (Nasdaq: ARTV) reported third-quarter 2025 results and clinical updates for AlloNK (AB-101). Key highlights include FDA Fast Track designation in October 2025 for AlloNK in refractory rheumatoid arthritis (RA) with rituximab, and >100 patients treated across oncology and autoimmune indications. The company reported $123.0 million in cash, cash equivalents, and investments as of September 30, 2025, with a runway into Q2 2027. Initial clinical response data from >15 refractory RA patients are expected in 1H 2026, and FDA discussions on pivotal trial design are planned for 1H 2026.
Financials: R&D expense was $17.6M vs $13.5M prior year; G&A was $5.3M vs $4.8M; other income, net $1.4M vs $0.9M; net loss $21.5M vs $17.5M. CFO transition announced, with leadership change effective end of December 2025.
Artiva Biotherapeutics (Nasdaq: ARTV) will host a virtual webcast on November 12, 2025 at 8 a.m. ET to discuss initial safety and translational data for AlloNK® plus anti-CD20 antibodies in autoimmune disease.
Key disclosed items: initial safety data in 32 patients reporting a favorable tolerability profile and outpatient feasibility; translational results showing uniform, deep B-cell depletion; a high-sensitivity B-cell assay with 10- to 50-fold greater sensitivity; and characterisation of the unmet need in refractory rheumatoid arthritis. A live Q&A and replay will be available via the company website.
Artiva Biotherapeutics (Nasdaq: ARTV) announced that management will participate in investor conferences in November 2025 and will offer live webcasts and replays.
Key events: a fireside chat at TD Cowen's Immunology & Inflammation Summit (Virtual) on Wednesday, November 12, 2025 at 11:30 a.m. ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 12:00 p.m. GMT. Management is available for investor meetings for registered attendees. Live webcasts will be accessible via the Investors section on Artivabio.com, with replay available for 90 days after each event.
Artiva Biotherapeutics (Nasdaq: ARTV) prioritized refractory rheumatoid arthritis (RA) as the lead indication for AlloNK (AB-101) and announced that the U.S. FDA granted Fast Track Designation for AlloNK in refractory RA in combination with rituximab. The company reported >20 patients treated with AlloNK plus monoclonal antibody therapy at 1 billion and 4 billion cell doses across multiple autoimmune indications.
Emerging translational and safety data are expected in mid-November; clinical response data from >15 refractory RA patients are expected in 1H 2026. FDA interactions are planned in 1H 2026 to discuss a potential pivotal trial.